Pharmacol Ther. 2017 Feb 20. pii: S0163-7258(17)30065-7. doi: 10.1016/j.pharmthera.2017.02.041. [Epub ahead of print]
Pisanti S1, Malfitano AM2, Ciaglia E2, Lamberti A2, Ranieri R2, Cuomo G2, Abate M2, Faggiana G2, Proto MC3, Fiore D3, Laezza C4, Bifulco M5.
Abstract
Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids. Δ9-THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both compounds have been suggested. However, CBD is recently emerging as a therapeutic agent in numerous pathological conditions since devoid of the psychoactive side effects exhibited instead by Δ9-THC. In this review, we highlight the pharmacological activities of CBD, its cannabinoid receptor-dependent and -independent action, its biological effects focusing on immunomodulation, angiogenetic properties, and modulation of neuronal and cardiovascular function. Furthermore, the therapeutic potential of cannabidiol is also highlighted, in particular in neurological diseases and cancer.
Copyright © 2017. Published by Elsevier Inc.
KEYWORDS:
Cannabis; cancer; cannabidiol; endocannabinoid system; neurological diseases
- PMID: 28232276
- DOI: 10.1016/j.pharmthera.2017.02.041
- [PubMed – as supplied by publisher]
-
Publication Types
